NEW YORK (360Dx) – Abreos Biosciences is developing a portfolio of assays that could be used, it said, to determine whether a patient is metabolizing the right dosage of biologic drugs targeting cancers, neurological disorders, and autoimmune diseases.

The San Diego-based firm does not have any assays on the market yet, but if it does get to the point of commercialization, it plans to make them available as laboratory-developed tests, with visions of bringing them to market as point-of-care tests, its CEO Bradley Messmer said.